G. Ross

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Stephen Chia, Tamas Hickish, V. Harvey et al. · Annals of Oncology · 2013 · 1.3K citations

Medicine, Oncology, Pharmacology +14

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

W. ten Bokkel Huinink, Stephen Lane, G. Ross · Annals of Oncology · 2003 · 130 citations · Full text

Medicine, Gynecology, Oncology +13

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

Daniel J. Lenihan, Thomas Suter, Melissa Brammer et al. · Annals of Oncology · 2011 · 122 citations · Full text

Pharmacy, Cardiology, Oncology +12

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

Martin Gore, Amit M. Oza, Gordon Rustin et al. · European Journal of Cancer · 2002 · 110 citations

Medicine, Gynecology, Oncology +12

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Stan B. Kaye, Christopher Poole, Anna Dańska-Bidzińska et al. · Annals of Oncology · 2012 · 91 citations · Full text

Medicine, Gynecology, Oncology +17